CSD/BSE&NSE/PR/2025-2026
July 16, 2025

To
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai – 400001

Scrip Code: 530239

To
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400051

Scrip Symbol: SUVEN

Dear Sir/Madam,

Sub: News Release

With reference to above subject, please find enclosed News Release of our company titled **"Suven Life Sciences announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant, an α4β2 Antagonist representing a Novel Mechanism of Action for the treatment of Major Depressive Disorder"**

This is for your information and record.

Thanking you.
Yours faithfully,
For **Suven Life Sciences Limited**

Shrenik Soni
Digitally signed by Shrenik Soni
Date: 2025.07.16 11:57:55 +05'30'

Shrenik Soni
Company Secretary

Encl.: as above

News Release

Suven Life Sciences announces First Patient Randomized in Phase-2b Clinical Trial of Ropanicant, an α4β2 Antagonist representing a Novel Mechanism of Action for the treatment of Major Depressive Disorder.

- *Phase-2b trial builds on promising safety and efficacy from a positive Phase-2a study.*
- *Study being conducted exclusively in USA under US FDA IND.*
- *Topline data expected in the second half of 2026.*

Hyderabad, India, 16-July-2025 - Suven Life Sciences, a clinical stage biopharmaceutical company discovering and developing novel medicines to treat Central Nervous System (CNS) disorders, today announced that the **first patient has been randomized in its Phase-2b clinical trial evaluating Ropanicant,** a novel oral α4β2 nicotinic acetylcholine receptor (nAChR) antagonist, for the treatment of **Major Depressive Disorder (MDD).**

The Phase-2b double blinded, placebo controlled study builds on the positive results of the completed Phase-2a trial, which demonstrated favorable safety, clinically meaningful and significant improvement in depressive symptoms from baseline based on the Montgomery-Åsberg Depression Rating Scale (MADRS) score, with indication of rapid onset of action in MDD patients distinguishing Ropanicant from existing standard therapies. Insights from Phase-2a evolved the study design, dose selection, and dosing regimen for the current Phase-2b trial being conducted in exclusively in USA under FDA IND.

"Randomizing the first patient in our Phase-2b study of Ropanicant is an important milestone for Suven Life Sciences. It reflects our continued commitment to developing innovative treatments for patients suffering from MDD." said **Mr. Venkat Jasti,** Chairman and MD of Suven Life Sciences.

"There is a significant unmet medical need for antidepressants that are effective, rapid onset of action and to be well tolerated. Ropanicant, with its unique, novel mechanism of action as an α4β2 antagonist, combined with its rapid onset, no sexual side effects, potential pro-cognitive benefits, achieves the position as a first-in-class, differentiated clinical candidate that could reshape the approach to the treatment of Major Depressive Disorders (MDD)." said **Mr. Ramakrishna Nirogi,** Ph. D., President & Chief Scientific Officer of Suven Life Sciences**.**

About Ropanicant Phase-2b Study: The Phase-2b study (CTP2S2911A4B2) is a randomized, double-blind, placebo-controlled trial that will enroll approximately 195 patients across 35 sites in the USA for a treatment duration of six weeks. The study will evaluate the efficacy and safety of Ropanicant in patients with major depressive disorder, compared to placebo, in improving symptoms of depression as measured by the MADRS.

For more information about the Phase-2b study visit ClinicalTrials.gov. Identifier NCT06836063. Topline results from this Phase-2b trial is anticipated in the second half of 2026.

About Ropanicant (SUVN-911): Ropanicant is a novel, potent and selective α4β2 nAChR antagonist, and is being developed for the treatment of MDD. Ropanicant has shown robust efficacy in various animal models of depression. Ropanicant may have potential to overcome significant limitations of existing treatments for depressive disorders by providing a rapid onset of action, avoiding sexual dysfunction, and enhancing cognitive functions. Ropanicant non-clinical safety has been established in various safety pharmacology and toxicity studies (up to 9-month duration). Ropanicant was evaluated in healthy subjects in two Phase-1 studies (NCT03155503 and NCT03551288). It was well tolerated up to the highest tested dose in both single and multiple ascending dose studies. No significant effect of food and age was noted on Ropanicant pharmacokinetics. In the Phase 2a trial (NCT06126497), Ropanicant demonstrated a favorable safety profile and produced clinically meaningful and significant improvements in depressive symptoms, as measured by the MADRS score. Ropanicant intellectual property rights are owned by Suven and are well protected in all major markets.

About Suven Life Sciences: Suven Life Sciences Limited (Suven) is focused on the discovery and clinical development of innovative medicines that address unmet medical needs in central nervous system (CNS) disorders. We have portfolio of advanced stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), Sleep disorders, Major depressive disorders (MDD), Parkinson's disease (PD), Schizophrenia, Pain disorders, and Gastrointestinal disorders. Suven has 5 clinical stage assets across focus areas: Masupirdine (SUVN-502) for the treatment of agitation in patients with dementia of the Alzheimer's type (Phase 3 study ongoing); Samelisant (SUVN-G3031) for excessive daytime sleepiness (EDS) in narcolepsy (Phase 2 study for EDS completed; Phase 2 study for Cataplexy and pivotal Phase 3 study for EDS are in planning); Ropanicant (SUVN-911) for MDD (Open-label Phase 2a study completed; Double blind randomized Placebo-controlled Phase 2b study ongoing); Usmarapride (SUVN-D4010) for cognitive disorders (Phase 2 study in planning), SUVN-I6107 for cognitive disorders (Phase 1 study ongoing). In addition to these clinical assets, we have 7 projects in research pipeline across multiple indications. Suven owns all intellectual property rights for its assets in all major markets.

For more information, please visit our website http://www.suven.com

Risk Statement: Except for historical information, all the statements, expectations, and assumptions, including expectations and assumptions, contained in this news release may be forward-looking statements that involve several risks and uncertainties. Although Suven attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. Other important factors which could cause results to differ materially including outsourcing trends, economic conditions, dependence on collaborative partnership programs, retention of key personnel, technological advances, and continued success in growth of sales that may make our products/services offerings less competitive; Suven may not undertake to update any forward-looking statements that may be made from time to time.